Simultaneous measurement of collagen type-VI-related antigen and procollagen type-III-N-propeptide levels in bronchoalveolar lavage

Schaberg, T.; Orzechowski, K.; Oesterling, C; Lode, H.; Schuppan, Detlef

doi:10.1183/09031936.94.07071221

Cited by 8 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although with a lower significance level, behaviour of serum PICP in sarcoidosis parallels that of serum PIIINP, suggesting that the metabolism of both types of collagen is accelerated. A similar occurrence has been shown for PIIINP and type VI collagen related peptide in BAL fluid of sarcoid patients [25].…”

Section: Discussionsupporting

confidence: 82%

Serum type I and type III procollagen peptide levels in sarcoidosis

et al. 1996

View full text Add to dashboard Cite

Type I and type III are the most abundant collagens in the lung. The aim of our study was to compare type I and III procollagen peptides in sera of sarcoid patients.Sixty eight patients with sarcoidosis were studied (19 with newly recognized disease, 7 with relapsing disease, 15 with chronic disease, and 27 in stable remission). Thirty healthy volunteers served as controls. The levels of procollagen I and III peptides were determined by radioimmunoassay. Angiotensin-converting enzyme (ACE) level was evaluated by means of a colorimetric assay.In patients with newly recognized sarcoidosis, both serum procollagen I and III peptide levels were increased with respect to controls (p=0.0014 and p<0.00001, respectively). There was a poor correlation between levels of procollagen I and III (r=0.26), whereas there was a closer correlation between procollagen III and ACE (r=0.69). Procollagen I peptide level did not identify patients in roentgenological stage III.In conclusion, in patients with newly recognized sarcoidosis there is a significant increase in the serum level of procollagen I peptide. However, procollagen I peptide is not a marker of sarcoid patients with fibrosis, i.e. stage III disease. Its clinical usefulness seems to be weaker than that of procollagen III peptide.

show abstract

Section: Discussionsupporting

confidence: 82%

Serum type I and type III procollagen peptide levels in sarcoidosis

et al. 1996

View full text Add to dashboard Cite

show abstract

“…LOW et al [11] found increased concentrations of PIIINP in the BALF of sarcoidosis patients but no correlation of the peptide levels with clinical severity. Serum-or BALF-PIIINP has been reported to be elevated also in various other studies [8,9,12,14,15,29]. O'CONNOR et al [14] concluded that BALF-PIIINP is a poor indicator of the course and prognosis of this disease, and that an increase in BALF-PIIINP levels may reflect increased type III collagen synthesis associated with inflammatory process, rather than development of chronic lung disease.…”

Section: Discussionmentioning

confidence: 99%

Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis

Lammi

Kinnula²,

Lähde³

et al. 1997

Eur Respir J

View full text Add to dashboard Cite

No single test is available to reliably assess the activity or prognosis of pulmonary sarcoidosis. In this study, we have evaluated two procollagen markers, aminoterminal propeptide of type III procollagen (PIIINP) and carboxyterminal propeptide of type I procollagen (PICP) in serum and bronchoalveolar lavage fluid (BALF) and compared them to other disease markers of pulmonary sarcoidosis, such as serum level of angiotensin converting enzyme (S-ACE) or serum interleukin-2 receptor (S-IL-2R). Bronchoalveolar lavage was performed in 40 sarcoidosis patients without (stages 0-I) and 20 patients with lung parenchymal involvement (stages II-III), as well as in 17 controls. Serum (S)- and BALF-PIIINP and PICP, S-ACE, S-IL-2R, BALF-albumin, BALF-lymphocytes and mast cells were determined in these patients. BALF-PIIINP was clearly and S-PIIINP slightly elevated in sarcoidosis compared to the controls. Similarly BALF-PICP, but not S-PICP, was significantly higher in sarcoidosis. BALF-PIIINP, but not BALF-PICP correlated with S-ACE and S-IL-2R levels. Patients with lung parenchymal disease had higher S-ACE and BALF-PIIINP, but neither S-IL-2R, S-PIIINP nor S- or BALF-PICP were elevated. S-PIIINP and S-IL-2R but not S-ACE were higher in symptomatic than nonsymptomatic patients. Symptomatic patients with parenchymal disease had elevated BALF-PIIINP whereas in the symptomatic nonparenchymal group S-PIIINP was elevated. In conclusion, this is the first study to evaluate carboxyterminal propeptide of type I procollagen in sarcoidosis and showed elevated levels in bronchoalveolar lavage fluid. In contrast to the levels of bronchoalveolar lavage fluid aminoterminal propeptide of type III procollagen, levels of carboxyterminal propeptide of type I procollagen did not correlate with serum level of angiotensin converting enzyme and serum interleukin-2 receptor levels, suggesting that carboxyterminal propeptide of type I procollagen may be less suitable disease marker in sarcoidosis than aminoterminal propeptide of type III procollagen. However, the role of carboxyterminal propeptide of type I procollagen as an indicator of fibrogenesis must be further studied.

show abstract

“…There is a growing experimental evidence that PIIINP levels are primarily due to increased collagen type-III production. PIIINP reflects the cleavage of procollagen peptide from the N-terminal end of collagen type-III during fibril growth [ 12,22]. However, this method should use radioactivity.…”

Section: Discussionmentioning

confidence: 99%

Enzyme-Linked Immunosorbent Assay for Serum Procollagen Type III Peptide in Rats with Hepatic Fibrosis.

Cho

Lee

1998

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. The process of hepatic fibrosis, and the changes in contents of hepatic hyproxyproline (HYP) and serum procollagen type III peptide (PIIINP) were examined in two rat models for hepatic fibrosis, i.e. bile duct ligation/scission (BDL/s)-and dimethylnitrosamine (DMN)-induced models. In addition, an expression of type III collagen mRNA in the liver of BDL/s model was also examined. In BDL/ s model, hepatic fibrosis started at 2 weeks after operation (WAO) and cirrhosis with prominent bile duct hyperplasia was detected at and after 5 WAO. Serum PIIINP content measured using a modified double armed inhibition enzyme-linked immunosorbent assay (ELISA) method proposed by us started to increase at 1 WAO and continued to increase thereafter. Hepatic HYP content measured colorimetrically started to increase at 3 WAO and it continued to increase until 7 WAO. An expression of type III collagen mRNA in the liver was enhanced at and after 2 WAO, especially at 4 and 5 WAO. In DMN model, marked hepatic fibrosis was detected at 1 week after the last DMN administration (WAA), and the degree of fibrosis was apparently reduced at 4 WAA. Serum PIIINP content prominently increased at 1 WAA and decreased at and after 3 WAA. Hepatic HYP content showed a marked increase at 1 WAA and decreased thereafter. The present results indicated that the sequences of hepatic fibrosis, hepatic HYP content and serum PIIINP content were well correlated with each other in both BDL/s and DMN models. In conclusion, ELISA system for the detection of serum PIIINP content is considered to be reliable method for assessment of cirrhotic liver, and the present two rat models for liver fibrosis/cirrhosis seems to be a good tool for researching antifibrotic agents. -KEY WORDS: enzyme-linked immunosorbent assay, hepatic fibrosis model, rat, serum procollagen type III peptide.J. Vet. Med. Sci. 60(11): 1213-1220, 1998 and hepatocyte necrosis. Namely, bile duct ligation/scission (BDL/s) is recommended as a useful method for producing progressive and reproducible biliary fibrosis in rats without prominent hepatocyte necrosis and severe inflammation [9,19]. In addition, treatment with dimethylnitrosamine (DMN) is also known to have an advantage to induce fibrosis in rats in a relatively short period (3 weeks) with slight inflammation and hepatocyte necrosis [2,26]. The aim of this study is to establish a non-radioactive method, i.e. enzyme-linked immunosorbent assay (ELISA) to evaluate serum PIIINP using BDL/s-and DMN-induced hepatic fibrosis in rats. MATERIALS AND METHODS Animals:Two hundred male Sprague-Dawley rats (11 weeks old) obtained from Laboratory Animal Center of Seoul National University in Korea were used. The animals were kept in an animal room maintained at 23 ± 2°C with 60 ± 10% r.h. with 12 hr-light and 12 hr-dark cycle, and were given normal pelleted diet (Shinchon, Korea) and water ad libitum.Treatments: As to bile duct ligation/scission (BDL/s) model, the hepatic biliary system was occluded by distal and proximal ligation using 4-0 silk (P...

show abstract

Simultaneous measurement of collagen type-VI-related antigen and procollagen type-III-N-propeptide levels in bronchoalveolar lavage

Cited by 8 publications

References 22 publications

Serum type I and type III procollagen peptide levels in sarcoidosis

Serum type I and type III procollagen peptide levels in sarcoidosis

Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis

Enzyme-Linked Immunosorbent Assay for Serum Procollagen Type III Peptide in Rats with Hepatic Fibrosis.

Contact Info

Product

Resources

About